Combination therapy of immunotherapy plus chemotherapy shows promise in clinical trials for B cell Acute Lymphoblastic Leukemia. Improved efficacy compared to chemotherapy alone, lower relapse rates, and manageable side effects.

The FDA has recently approved an injectable form of an immunotherapy (Opdivo Qvantig). Now, 30-minute IV infusions can be shortened to 5-minute subcutaneous injections with the same efficacy and safety.

An abnormal prenatal blood test result, not attributable to the fetus, could suggest possible hidden cancer diagnosis in the mother.

Immunotherapy for ALL in Children